Hot Pursuit     16-Sep-22
Shilpa Medicare gets tentative approval for hepatitis drug
The pharmaceutical company on Friday announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its ANDA, Tenofovir Alafenamide Tablets.
The Abbreviated New Drug Application (ANDA) was filed as ‘first to file' submission on NCE -1 date, said the drug maker.

Tenofovir Alafenamide Tablets is a generic equivalent of reference listed drug (RLD) Vemlidy tablets of Gilead Sciences Inc.

Tenofovir alafenamide is used for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.

According to IQVIA MAT Q2 2022 data, Tenofovir Alafenamide Tablets had revenue of $498.14 million in the United States.

Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.

The company's consolidated net profit tumbled 46.5% to Rs 0.85 crore on 10% increase in net sales to Rs 261.16 crore in Q1 FY23 over Q1 FY22.

Shares of Shilpa Medicare were down 0.20% to Rs 387.25 on the BSE.

Previous News
  Sensex declines 150 pts; realty shares slide for 5th day
 ( Market Commentary - Mid-Session 04-Oct-24   10:32 )
  Shilpa Medicare arm gets CEP from EDQM for Desmopressin
 ( Hot Pursuit - 04-Oct-24   08:40 )
  Shilpa Medicare announces receipt of CEP from EDQM for API 'Desmopressin'
 ( Corporate News - 03-Oct-24   17:12 )
  Sensex gains 233 pts; private banks rally for 6th day
 ( Market Commentary - Mid-Session 19-Sep-24   14:31 )
  Shilpa Medicare arm appoints Sridevi Khambhampaty as CEO
 ( Hot Pursuit - 19-Sep-24   13:35 )
  Shilpa Biologicals appoints CEO
 ( Corporate News - 19-Sep-24   13:35 )
  Shilpa Medicare hits life high on submission of new drug application to USFDA
 ( Hot Pursuit - 04-Sep-24   15:24 )
  Shilpa Medicare update on its CDMO customer - Unicycive Therapeutics
 ( Corporate News - 04-Sep-24   15:14 )
  Shilpa Medicare hits record high on USFDA nod for cancer drug
 ( Hot Pursuit - 27-Aug-24   14:43 )
  Shilpa Medicare hits 52-week high on successful trial of fatty liver drug
 ( Hot Pursuit - 26-Aug-24   12:41 )
  Shilpa Medicare successfully completes phase-3 clinical studies of NorUDCA
 ( Corporate News - 26-Aug-24   10:30 )
Other Stories
  UCO Bank’s total advances jump 19% YoY in Q2 FY25
  04-Oct-24   15:15
  Vakrangee Ltd leads losers in 'A' group
  04-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  04-Oct-24   14:45
  GRSE bags Rs 226-cr LoA from West Bengal Govt
  04-Oct-24   14:40
  Volumes soar at Avenue Supermarts Ltd counter
  04-Oct-24   14:30
  Real Estate stocks edge lower
  04-Oct-24   14:00
  Auto stocks edge lower
  04-Oct-24   14:00
  Utilties stocks edge lower
  04-Oct-24   14:00
  HDFC Bank Ltd down for fifth straight session
  04-Oct-24   13:35
  Power Grid Corporation of India Ltd down for fifth straight session
  04-Oct-24   13:35
Back Top